NBIX
Neurocrine Biosciences, Inc.
$106.27
Earnings Summary
Revenue | $378.2Mn |
Net Profits | $-16.9Mn |
Net Profit Margins | -4.47% |
PE Ratio | 816.23 |
Highlights
Neurocrine Biosciences, Inc.’s revenue jumped 30.91% since last year same period to $378.2Mn in the Q2 2022. On a quarterly growth basis, Neurocrine Biosciences, Inc. has generated 21.76% jump in its revenue since last 3-months.
Neurocrine Biosciences, Inc.’s net profit fell -139.95% since last year same period to $-16.9Mn in the Q2 2022. On a quarterly growth basis, Neurocrine Biosciences, Inc. has generated -221.58% fall in its net profits since last 3-months.
Neurocrine Biosciences, Inc.’s net profit margin fell -130.52% since last year same period to -4.47% in the Q2 2022. On a quarterly growth basis, Neurocrine Biosciences, Inc. has generated -199.85% fall in its net profit margins since last 3-months.
Neurocrine Biosciences, Inc.’s price-to-earnings ratio after this Q2 2022 earnings stands at 816.23.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Neurocrine Biosciences, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | 0.59 |
EPS Estimate Current Year | 0.59 |
Highlights
Neurocrine Biosciences, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.59 - a 68.57% jump from last quarter’s estimates.
Neurocrine Biosciences, Inc.’s earning per share (EPS) estimates for the current year stand at 0.59.
Key Ratios
Key ratios of the Neurocrine Biosciences, Inc. post its Q2 2022 earnings
Return on Assets (ROA) | 0.05 |
Return on Equity (ROE) | 0.01 |
Dividend Per Share (DPS) | 0 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Neurocrine Biosciences, Inc.’s return on assets (ROA) stands at 0.05.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Neurocrine Biosciences, Inc.’s return on equity (ROE) stands at 0.01.
Neurocrine Biosciences, Inc. declared 0 dividend per share during the earnings announcement for Q2 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-04 | 0.35 | 0.14 | -60% |
Company Information
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
Organisation | Neurocrine Biosciences, Inc. |
Headquarters | 12780 El Camino Real, San Diego, CA, United States, 92130 |
Employees | 845 |
Industry | Health Technology |
CEO | Kevin Gorman |